



**SUPPLEMENTAL FIGURE 1.** Representative *in vitro* saturation binding curves of  $^{111}\text{In-DTPA-pertuzumab}$  to SKBr-3 (A) or MDA-MB-361 (B) cells treated for 72 h with trastuzumab (14  $\mu\text{g/mL}$ ) and untreated controls. The  $B_{\text{max}}$  values were calculated from the specific binding by fitting a plot of total cell-bound  $^{111}\text{In-DTPA-pertuzumab}$  (nmols) vs. the concentration of total added radioligand (nmols/L) to a 1-site saturation binding model using Prism® Ver. 4.0 software and then mathematically deriving the non-specific binding for subtraction from the total binding.

### SUPPLEMENTAL TABLE 1

Tumor Uptake (%ID/g) of <sup>111</sup>In-DTPA-Pertuzumab of Individual Athymic Mice Implanted Subcutaneously with MDA-MB-361 Human Breast Cancer Xenografts at 72 Hours Post-Injection

Mouse	3-Day Treatment		3-Week Treatment	
	PBS	Trastuzumab	PBS	Trastuzumab
1	39.5	16.2	39.4	7.2
2	32.5	13.3	41.1	7.2
3	20.2	10.9	23.2	8.1
4	21.8	n/a	n/a	7.8

n/a: not available

### SUPPLEMENTAL TABLE 2

Immunohistochemical Analysis of Excised MDA-MB-361 Human Breast Cancer Xenografts Stained for HER2

PBS*	Trastuzumab 3 days*	Trastuzumab 3 weeks
25 ± 17	30 ± 13	n/a <sup>†</sup>

\* Tumors were scored as the percentage of strong, complete membrane staining. Results are presented as the mean ± SD of 3 tumors.

<sup>†</sup> Not applicable. Too few viable tumor cells to assign a score.